[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haemorrhoids\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haemorrhoids":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100642507","evaluation-of-the-effectiveness-of-micronized-purified-flavonoid-fraction-mpff-in-patients-with-haemorrhoids-undergoing-minimally-invasive-surgical-interventions-100642507",false,"NCT07647172","Evaluation of the Effectiveness of Micronized Purified Flavonoid Fraction (MPFF) in Patients With Haemorrhoids Undergoing Minimally Invasive Surgical Interventions","Evaluation of the Effectiveness of Micronized Purified Flavonoid Fraction (MPFF) as Part of the Conservative Therapy and Impact on Quality of Life and Satisfaction With Treatment in the Real-life Clinical Practice in Patients With Haemorrhoids Undergoing Minimally Invasive Surgical Interventions","DEMAND HD","Inclusion Criteria:\n\n* Males and females aged over 18 years.\n* Informing the patient in writing about the inclusion in the study and his\u002Fher consent to participate in it.\n* Absence of conditions requiring urgent medical care.\n* The patient was diagnosed with chronic hemorrhoids of grade 2 or 3 according to Goligher classification.\n* The patient is scheduled to undergo one of the listed types of minimally invasive surgical treatment within 7 ± 2 days from the inclusion in the study (V0):\n* laser vaporization (laser submucosal destruction or ablation);\n* transanal dearterialization (hemorrhoidal artery ligation);\n* transanal dearterialization + laser vaporization (laser submucosal destruction or ablation);\n* transanal dearterialization + sclerotherapy.\n* No venoactive drug treatment within 4 weeks prior to inclusion in the study.\n* The patient has been prescribed with MPFF at the inclusion visit, or it is planned to prescribe MPFF-containing drug in the postoperative period (for cluster 1 sites), or the patient has not been prescribed with any systemic venoactive drug, and it is not planned to prescribe it the postoperative period (for cluster 2 sites).\\*\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding, or planning for pregnancy during the study or at least in two months after its completion.\n* Confirmed or suspected malignancy.\n* Severe somatic disorder (of heart or blood vessels, lungs, kidneys, pancreas, or liver), accompanied by the organ function decompensation.\n* Mental disorder.\n* Contraindications for examination.\n* Predicted unwillingness of the patient to follow the protocol of treatment and supervision, poor adherence to treatment.\n* Patient's participation in any interventional\u002Fobservational study at the present time.\n* Patients who received venoactive drugs in the 4 weeks prior to Visit 0 (inclusion visit).","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Evaluation of the effectiveness of micronized purified flavonoid fraction (MPFF) as part of the conservative therapy and impact on quality of life and satisfaction with treatment in the real-life clinical practice in patients with haemorrhoids undergoing minimally invasive surgical interventions",[25],"Haemorrhoids","NOT_YET_RECRUITING","2026-06-09",{"date":29,"type":30},"2026-06-15","ACTUAL",{"date":32,"type":21},"2026-07-01",{"date":34,"type":21},"2027-04-01",{"name":36,"class":37},"Servier Russia","INDUSTRY",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100529204","radiofrequency-ablation-vs-doppler-guided-haemorrhoidal-artery-ligation-in-the-treatment-of-haemorrhoidal-disease-100529204","NCT06170736","Radiofrequency Ablation vs Doppler-guided Haemorrhoidal Artery Ligation in the Treatment of Haemorrhoidal Disease","Radiofrequency Haemorrhoidal Thermoablation Versus Doppler-guided Haemorrhoidal Artery Ligation With Mucopexy in the Treatment of Haemorrhoidal Disease: a Multicenter Randomized Non-inferiority Trial","RADIOLIGA","Inclusion Criteria:\n\n* Major patient,\n* With symptomatic Grade II or III haemorrhoidal disease,\n* Requiring surgical management,\n* Patient able to understand the protocol and having given written informed consent to participate in the study,\n* Patient affiliated to the social security system or entitled to it.\n\nExclusion Criteria:\n\n* Hemostasis disorders\n* Active external haemorrhoidal disease (thrombosis)\n* History of surgical procedure for treatment of haemorrhoids (instrumental treatment is not a contra-indication)\n* Associated proctological pathology (anal fissure, chronic suppuration, external rectal prolapse)\n* History of colorectal cancer\n* History of inflammatory bowel disease\n* History of rectal resection\n* Patient participating in another interventional clinical research protocol involving a drug or clinical investigation of a medical device\n* Patient who is pregnant, breastfeeding or able to procreate without effective contraception\\* at the time of inclusion\n* Patient under guardianship, curators or deprived of liberty.\n* Patient under court protection.\n\n  * oral contraceptive (pill), monthly vaginal ring, weekly transdermal patch, subcutaneous implant, intrauterine devices (IUD), or sterilisation.","80 Years",{"count":48,"type":21},168,"INTERVENTIONAL",[51],"NA","Surgical treatment of grade II\u002FIII internal haemorrhoidal disease is indicated in the case of medical and\u002For instrumental treatment failure. Minimal invasive alternatives to haemorrhoidectomy have been introduced in the last decades to treat grade II\u002FIII haemorrhoids. Doppler-Guided haemorrhoidal artery ligation (DGHAL) represents a good therapeutic option in this condition with good short and mid-term outcomes but postoperative recurrence rates up to 35% at 5 years.\n\nRecently, a technique of radiofrequency ablation (RFA) has been introduced with promising outcomes. A recent systematic review reported a significant improvement of preoperative symptoms and a recurrence rate \\\u003C 5%.\n\nTo date, there is no study comparing DGHAL to RFA in the treatment of grade II\u002FIII haemorrhoids.\n\nThe aim of this study is to demonstrate the non-inferiority in terms of failure rate of haemorrhoidal radiofrequency ablation compared to Doppler-guided haemorrhoidal artery ligation, associated with mucopexy, in the treatment of grade II and III haemorrhoidal disease",[25,54,55],"Internal Haemorrhoids","Grade II\u002FIII Haemorrhoids",[25,57,58],"Radiofrequency","Doppler-guided haemorrhoidal artery ligation","RECRUITING","2026-03-12",{"date":62,"type":30},"2026-03-13",{"date":64,"type":30},"2024-02-21",{"date":66,"type":21},"2030-09-15",{"name":68,"class":69},"Centre Hospitalier Departemental Vendee","OTHER",18]